RIV Capital (OTCMKTS:CNPOF – Get Free Report) and Organon & Co. (NYSE:OGN – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends.
Profitability
This table compares RIV Capital and Organon & Co.’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| RIV Capital | N/A | N/A | N/A |
| Organon & Co. | 3.41% | 88.97% | 6.03% |
Insider & Institutional Ownership
77.4% of Organon & Co. shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| RIV Capital | 0 | 0 | 0 | 0 | 0.00 |
| Organon & Co. | 2 | 5 | 0 | 0 | 1.71 |
Organon & Co. has a consensus price target of $11.40, indicating a potential downside of 17.27%. Given Organon & Co.’s stronger consensus rating and higher possible upside, analysts clearly believe Organon & Co. is more favorable than RIV Capital.
Earnings and Valuation
This table compares RIV Capital and Organon & Co.”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| RIV Capital | N/A | N/A | N/A | N/A | N/A |
| Organon & Co. | $6.22 billion | 0.58 | $187.00 million | $0.77 | 17.90 |
Organon & Co. has higher revenue and earnings than RIV Capital.
Summary
Organon & Co. beats RIV Capital on 8 of the 8 factors compared between the two stocks.
About RIV Capital
RIV Capital Inc., formerly known as Canopy Rivers Inc., is a venture capital firm. The firm is a stage agnostic, with seed to sale, although it prefers to invest in series A to C rounds. It prefers to make investments in cannabis sector with focus on burgeoning marijuana companies and sectors like agriculture and food sciences, production, processing, pharmaceuticals and biotechnology, software and data, hardware, consumer products and accessories, wellness products, retail and distribution, and media and content. The firm also focuses on beverages, capsules and concentrates, edibles, dry flower / pre-rolls, vaporizers and hardware, pet products, and topicals. In agriculture and food sciences firm focuses in invest plant science, soil science, food science, animal science and environmental science. In production firm focuses in Indoor cultivation, greenhouse cultivation, outdoor cultivation, nursery cultivation and fermentation. In processing firm focuses in harvesting, extraction and purification, packaging, food and beverage processing and laboratory testing services. In pharmaceuticals and biotechnology firm focuses in pharmaceutical discovery and development, delivery method (ex: pill, soft gel, tincture), biosynthetic derived cannabinoids and other molecules, medical devices (ex: inhalers) and lab equipment. In consumer products and accessories firm focuses in edibles, beverages, inhalable, cosmetics and cannabis consumption accessories. In retail and distribution firm focuses in licensed brick and mortar retailers, pharmacies, online consumer marketplaces, delivery services, and others. The firm invests in opportunities globally. The firm prefers to invest in check sizes have ranged from CA$1 million ($0.71 million) to $40 million ($28.45 million), but more typical investment range is between CA$5 million ($3.6 million) to CA$10 million ($7.1 million). The firm is focused on making minority stake investments. Firm employ diverse investment structures including debt, preferred and common equity, and production-linked royalties. RIV Capital Inc. was founded on 2017 and is based in Toronto, Canada.
About Organon & Co.
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Receive News & Ratings for RIV Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RIV Capital and related companies with MarketBeat.com's FREE daily email newsletter.
